Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity
July 23, 2024 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
-- LB54640 has shown targeted effect on MC4R without hyperpigmentation -- BOSTON, July 23, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical...
Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
July 23, 2024 07:30 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, July 23, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
July 11, 2024 16:01 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, July 11, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer
July 08, 2024 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency
June 28, 2024 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
- European Commission decision anticipated in the second half of 2024 - BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
June 11, 2024 16:01 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, June 11, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
June 03, 2024 16:02 ET
|
Rhythm Pharmaceuticals, Inc.
Rhythm presents first-ever hypothalamic obesity patient-reported experiences with hyperphagia and positive changes in energy and sleep at ENDO2024
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
June 03, 2024 08:02 ET
|
Rhythm Pharmaceuticals, Inc.
RYTM CEO at David Meeker at Goldman Sachs Global Healthcare Conference June 10.
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
May 22, 2024 04:00 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
May 09, 2024 16:01 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...